会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Tetrahydrobenzindolone derivatives
    • 四氢苯并吲哚酮衍生物
    • US6077840A
    • 2000-06-20
    • US331294
    • 1999-06-18
    • Kenichi KuriharaRie ShineiYasushi KurataYuji TabataKiyoshi TanabeTsuneo Okonogi
    • Kenichi KuriharaRie ShineiYasushi KurataYuji TabataKiyoshi TanabeTsuneo Okonogi
    • C07D209/60C07D401/12C07D403/12C07D405/12C07D409/12C07D521/00A61K31/535A61K31/40A61K31/44A61K31/50C07D233/02
    • C07D231/12C07D209/60C07D233/56C07D249/08C07D401/12C07D403/12C07D405/12C07D409/12
    • Compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic agents for progesterone-related diseases. Specifically, they are useful as carcinostatic agents for breast cancer and ovarian cancer, therapeutic agents for hysteromyoma, endometriosis, meningioma, and myeloma, abortifacients, oral contraceptive pills, and therapeutic and prophylactic agents for osteoporosis and climacteric disturbance. ##STR1## wherein R.sup.1 represents alkyl or aralkyl; R.sup.2 represents a hydrogen atom, alkylcarbonyl, cycloalkylcarbonyl, aromatic acyl, heteroaromatic acyl, saturated heterocyclic acyl, alkyl, alkenyl, aralkyl, carbamoyl, alkylcarbamoyl, aromatic carbamoyl, aralkylcarbamoyl, alkylaminocarbonyl, cycloalkylcarbamoyl, alkoxycarbonyl, aryloxycarbonyl, heteroaromatic thiocarbonyl, saturated heterocyclic thiocarbonyl, or alkyl-thiocarbamoyl: and R.sup.3 represents a hydrogen atom, a hydroxyl group, alkyloxy, alkylcarbonyloxy, alkylthio, or arylthio.
    • PCT No.PCT / JP97 / 04683 Sec。 371日期:1999年6月18日 102(e)1999年6月18日PCT 1997年12月18日PCT公布。 第WO98 / 27059号公报 日期:1998年6月25日公开了由下式(I)表示的化合物或其药学上可接受的盐及其制备方法。 所述化合物具有孕酮受体结合抑制活性,因此可用作孕酮相关疾病的治疗和预防剂。 具体地说,它们可用作乳腺癌和卵巢癌的制癌剂,子宫肌瘤,子宫内膜异位症,脑膜瘤和骨髓瘤的治疗剂,流产者,口服避孕药以及用于骨质疏松和更年期障碍的治疗和预防剂。 其中R1表示烷基或芳烷基; R 2表示氢原子,烷基羰基,环烷基羰基,芳香族酰基,杂芳基酰基,饱和杂环酰基,烷基,烯基,芳烷基,氨基甲酰基,烷基氨基甲酰基,芳香族氨基甲酰基,芳烷基氨基甲酰基,烷基氨基羰基,环烷基氨基甲酰基,烷氧基羰基,芳氧基羰基,杂芳硫基羰基,饱和杂环硫代羰基, 或烷基 - 硫代氨基甲酰基:和R3表示氢原子,羟基,烷氧基,烷基羰氧基,烷硫基或芳硫基。
    • 4. 发明授权
    • Dither method and printing apparatus
    • 抖动方式和打印装置
    • US6111658A
    • 2000-08-29
    • US986808
    • 1997-12-08
    • Yuji Tabata
    • Yuji Tabata
    • B41J2/52B41J2/525G06F3/12G06K15/12H04N1/405H04N1/52
    • G06K15/128H04N1/4051G06K2215/0094
    • A ROM in the control circuit of a color printer stores a threshold matrix. The individual elements of the threshold matrix correspond to print dots, the number of which is X.times.Y and which form 1 pixel in the original image. Values t (x, y) which are integral numbers not less than 0 are assigned one to each of the individual elements in a predetermined order. Using the threshold matrix, the CPU of the control circuit creates mask patterns for representing halftones. A value of 1 is subtracted from the tone number allotted to the tone of color of a pixel in an image to be printed, and the resultant value is substituted for a variable G. When a gradation for image data representing the pixel is given as "g", the condition required for setting ON (transferring toner to print) the dot specified by the coordinates (x, y) in the pixel in the case of the gradation "g" is expressed by the following formula (6):t (x, y).ltoreq.g.times.X.times.Y/G (6)Based on the threshold matrix and the formula (6), the CPU of the control section creates mask patterns in the case where the gradation "g" takes values 0 to G-1 in sequence, and develops those mask patterns in a RAM.
    • 彩色打印机的控制电路中的ROM存储阈值矩阵。 阈值矩阵的各个元素对应于打印点,其数量为XxY,并且在原始图像中形成1个像素。 作为不小于0的整数的值t(x,y)以预定顺序分配给每个单独元件1。 使用阈值矩阵,控制电路的CPU创建用于表示半色调的掩模图案。 从分配给要打印的图像中的像素的色调的色调数字中减去值1,并将结果值替换为变量G.当表示像素的图像数据的灰度被给定为“ g“时,在灰度”g“的情况下,将由像素中的坐标(x,y)指定的点所指定的ON(转印墨粉打印)所需的条件用下式(6)表示:t( (6)基于阈值矩阵和公式(6),控制部分的CPU在灰度“g”取0到G-1的情况下创建掩模图案 并且在RAM中开发出这些掩模图案。
    • 5. 发明授权
    • Tetrahydronaphthofuranone derivatives and process for producing the same
    • 四氢萘并呋喃酮衍生物及其制备方法
    • US06255339B1
    • 2001-07-03
    • US09117070
    • 1998-07-21
    • Kenichi KuriharaRie ShineiKiyoshi TanabeYasuo YamamotoKeiichi AjitoKaori MiyajimaYuji TabataShohei YasudaKuniaki TatsutaTsuneo Okonogi
    • Kenichi KuriharaRie ShineiKiyoshi TanabeYasuo YamamotoKeiichi AjitoKaori MiyajimaYuji TabataShohei YasudaKuniaki TatsutaTsuneo Okonogi
    • A61K3134
    • C07D307/92C07D407/12C07D407/14C07D409/12C07D417/12
    • Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic agents for progesterone-related diseases. Specifically, they are useful as abortifacients, oral contraceptive pills, carcinostatic agents for breast cancer and ovarian cancer, therapeutic agents for endometriosis, meningioma, and myeloma, and therapeutic and prophylactic agents for osteoporosis and climacteric disturbance. wherein R1 and R2 represent a hydroxyl group, alkyloxy, alkenyloxy, alkynyloxy, cycloalkyloxy, alkoxyalkyloxy, cycloalkyloxy containig one oxygen atom, aralkyloxy, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, cycloalkylcarbonyloxy, alkoxycarbonyloxy, aryloxy carbonyloxy, aralkylcarbonyloxy, aromatic acyloxy, heteroaromatic acyloxy, saturated heterocyclic carbonyloxy, alkylsulfonyloxy, aromatic sulfonyloxy, alkylcarbamoyloxy, aromatic carbamoyloxy, alkylcarbonylamino, or aromatic acylamino, provided that R1 may further represent a hydrogen atom, alkyl, alkenyl, or alkynyl; and R3, R4, and R5 each independently represent a hydrogen atom, alkyl or alkenyl.
    • 公开了由下式(I)表示的化合物及其药学上可接受的盐。 所述化合物具有孕酮受体结合抑制活性,因此可用作孕酮相关疾病的治疗和预防剂。 具体地说,它们可用作流产者,口服避孕药,乳腺癌和卵巢癌的制癌剂,子宫内膜异位症的治疗剂,脑膜瘤和骨髓瘤,以及骨质疏松症和更年期障碍的治疗和预防剂。其中R1和R2表示羟基, 烷氧基,链烯氧基,炔氧基,环烷氧基,烷氧基烷氧基,含有一个氧原子的环烷氧基,芳烷氧基,烷基羰基氧基,链烯基羰基氧基,炔基羰氧基,环烷基羰基氧基,烷氧基羰基氧基,芳氧基羰基氧基,芳烷基羰基氧基,芳香酰氧基,杂芳基酰氧基,饱和杂环羰氧基,烷基磺酰氧基,芳香磺酰氧基,烷基氨基甲酰氧基, 芳族氨基甲酰氧基,烷基羰基氨基或芳族酰氨基,条件是R 1可以进一步代表氢原子,烷基,烯基或炔基; 并且R 3,R 4和R 5各自独立地表示氢原子,烷基或链烯基。
    • 7. 发明授权
    • Sesquiterpene derivatives having progesterone receptor binding
inhibitory activity
    • 具有孕激素受体结合抑制活性的倍半萜衍生物
    • US5817816A
    • 1998-10-06
    • US878841
    • 1997-06-19
    • Kenzo HarimayaEmiko MagomeYuji TabataToru Sasaki
    • Kenzo HarimayaEmiko MagomeYuji TabataToru Sasaki
    • C07C69/738C07D303/48C07D307/92A61K31/365
    • C07D307/92C07C69/738C07D303/48
    • Sesquiterpene derivatives, represented by the following formulae (I) and (II), having progesterone receptor binding inhibitory activity are disclosed. They can be used as therapeutic and prophylactic agents for progesterone-related diseases, for example, as a carcinostatic agent for breast cancer or ovarian cancer, a therapeutic agent for hysteromyoma, endometriosis, meningioma, or myeloma, an abortifacient, an oral contraceptive pill, or a therapeutic or prophylactic agent for osteoporosis or climacteric disturbance. These compounds have no steroid skeleton and, hence, are considered to be advantageously free from side effect inherent in steroid such as found in conventional progesterone receptor binding inhibitors having a steroid skeleton. ##STR1## wherein R.sup.1 represents a hydrogen atom, a halogen atom, C.sub.1 -C.sub.5 alkoxy, or phenylthio; R.sup.2 represents C.sub.1 -C.sub.5 alkoxy or C.sub.2 -C.sub.5 alkanoyloxy; and ---- with letters a, b, c, d, and e attached thereto represent a double bond or a single bond; R.sup.3 has the same meaning as R.sup.2 ; and R.sup.4 represents C.sub.1 -C.sub.5 alkoxy.
    • 公开了具有孕酮受体结合抑制活性的由下式(I)和(II)表示的倍半萜衍生物。 它们可以用作孕激素相关疾病的治疗和预防剂,例如作为乳腺癌或卵巢癌的制癌剂,子宫肌瘤,子宫内膜异位症,脑膜瘤或骨髓瘤的治疗剂,流产者,口服避孕药, 或用于骨质疏松症或更年期障碍的治疗或预防剂。 这些化合物没有类固醇骨架,因此被认为有利地不含类固醇中固有的副作用,例如在具有类固醇骨架的常规孕酮受体结合抑制剂中发现。 (Ⅰ)其中R1表示氢原子,卤素原子,C1-C5烷氧基或苯硫基; R2代表C1-C5烷氧基或C2-C5烷酰氧基; 和+ E,uns ---- + EE与字母a,b,c,d和e表示双键或单键; R3与R2具有相同的含义; R4表示C1-C5烷氧基。